Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.

[1]  N. Wolmark,et al.  Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database. , 2020, Journal of the National Cancer Institute.

[2]  C. Lepage,et al.  Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). , 2020, Clinical colorectal cancer.

[3]  D. Cunningham,et al.  Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis , 2019, World Journal of Surgery.

[4]  M. Wagner,et al.  Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer , 2019, European Radiology.

[5]  C. Lepage,et al.  FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. , 2018, European journal of cancer.

[6]  J. Cataldo,et al.  Quality of life of patients with gastrointestinal cancers undergoing chemotherapy , 2018, Quality of Life Research.

[7]  C. Borel,et al.  Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  O. Bouché,et al.  Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Loriot,et al.  High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study , 2015, Molecular Cancer Therapeutics.

[10]  M. Loriot,et al.  Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study. , 2013 .

[11]  O. Bouché,et al.  Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  I. Sobhani,et al.  Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Pierre Michel,et al.  Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. , 2011, The Lancet. Oncology.

[14]  C. Tournigand,et al.  Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. , 2011, The oncologist.

[15]  C. Tournigand,et al.  Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Pignon,et al.  Randomised Trial Comparing Three Different Schedules of Infusional 5FU and Raltitrexed Alone as First-Line Therapy in Metastatic Colorectal Cancer , 2006, Oncology.

[17]  L. Schwartz,et al.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Scheithauer,et al.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.